Menu
← Oncology Approval Tracker
FDA DECISION ·
Trodelvy + Keytruda / Keytruda Qlex
sacituzumab govitecan-hziy with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph · Gilead Sciences / Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line combination for adults with unresectable locally advanced or metastatic TNBC whose tumors have a PD-L1 combined positive score (CPS) of at least 10 on an FDA-authorized test.
LAMPGEN ANALYSIS
Why it matters
This gives the PD-L1-selected first-line population an ADC and checkpoint inhibitor combination. ASCENT-04 and ASCENT-03 answer different treatment questions.
What research teams should watch
Verify the PD-L1 assay and CPS, record the correct pembrolizumab formulation and plan surveillance for both ADC and immune-mediated toxicity.
PRIMARY RECORDS